Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Exelixis, StemSynergy in CSNK1A activator deal

January 12, 2018 4:55 PM UTC

Exelixis Inc. (NASDAQ:EXEL) and StemSynergy Therapeutics Inc. (Miami, Fla.) partnered to discover and develop compounds targeting casein kinase 1 alpha (CSNK1A; CKI-alpha) to treat cancer.

The partners will conduct preclinical and clinical studies of compounds from StemSynergy's CSNK1A activator program. Exelixis will commercialize resulting products...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article